September 25, 2026 (View All Issues)
As AI Advances, How Will the Clinician’s Role Change?
Peter Clardy, MD, of Google for Health, described a fundamental challenge facing clinicians in the artificial intelligence (AI) era: AI capabilities are advancing rapidly at the same time clinicians are being asked to make decisions based on an ever-expanding volume of information. In oncology...
How One Nonprofit Is Providing Access to a Discontinued Investigational Drug for Children With a Rare Form of AML
Blood Cancer United (formerly the Leukemia & Lymphoma Society) recently announced it had acquired the remaining supply and rights to the investigational agent luveltamab tazevibulin, an antibody-drug conjugate targeting the folate receptor-1 alpha (FOLR1) molecule, from the drug’s manufacturer, ...
Old Habits Die Hard: Project Optimus and the Next Generation of KRAS G12C Inhibitors
The recent announcement1 that divarasib, a next-generation KRAS G12C inhibitor, improved both progression-free and overall survival compared with first-generation KRAS G12C inhibitors (ie, sotorasib, adagrasib) is an important scientific milestone in the treatment of KRAS G12C–mutated non–small...
Plant-Based Diet Linked to Lower Risk of Prostate Cancer Progression on Active Surveillance
For many men with low-risk prostate cancer, active surveillance means living with cancer while delaying—or potentially avoiding—surgery or radiation therapy. It also leaves many patients asking what they can do beyond “wait and watch.”
Findings presented at the 2026 American Urological Association ...
ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment
Three studies presented at the 2026 ASCO Breakthrough conference in Singapore focused on problems that can derail cancer care even when treatment is otherwise on track: nausea after starting morphine, continued smoking after a cancer diagnosis, and unrecognized frailty in older adults.
Although...
Trastuzumab Rezetecan Improves Progression-Free Survival in Chemotherapy-Refractory HER2-Positive Advanced Colorectal Cancer
The human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugate trastuzumab rezetecan significantly improved progression-free survival and produced higher response rates compared with standard-of-care therapy in patients with chemotherapy-refractory, HER2-positive, RAS/RAF...
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, HER2-negative...
Guideline Update Recommends Tailoring Breast Cancer Surveillance Based on Recurrence Risk
ASCO has published a guideline update offering clinicians new recommendations for breast cancer follow-up and surveillance after primary treatment.1
For this patient population, determining the optimal frequency and timing of visits can be a challenge, according to Expert Panel Co-Chair Maryam...
I Wasn’t Expecting Cancer at 22
Before I was diagnosed with advanced stage ovarian ependymoma, in 2025, when I was just 22, I didn’t know anything about cancer. I knew a few older adults who had had cancer, but that was the extent of my knowledge about the disease. Even to this day, I’m not sure I’ve completely wrapped my head...
Building Momentum: ASCO’s Geriatric Oncology CoP
The ASCO Geriatric Oncology Community of Practice (geriatric oncology CoP) convened for its first in-person meeting at McCormick Place in Chicago in May 2026. Since its inception in 2022, the geriatric oncology CoP has brought together clinicians, researchers, trainees, and patient advocates...
